Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Macular Degeneration HELP
Based on 10,823 articles since 2006
||||

These are the 10823 published articles about Macular Degeneration that originated from Worldwide during 2006-2015.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. 2015

Freund, K Bailey / Korobelnik, Jean-François / Devenyi, Robert / Framme, Carsten / Galic, John / Herbert, Edward / Hoerauf, Hans / Lanzetta, Paolo / Michels, Stephan / Mitchell, Paul / Monés, Jordi / Regillo, Carl / Tadayoni, Ramin / Talks, James / Wolf, Sebastian. ·*Vitreous Retina Macula Consultants of New York and Department of Ophthalmology, New York University Langone Medical Center, New York, New York; †Ophthalmology Service, CHU de Bordeaux, Bordeaux, France and INSERM, ISPED, Centre INSERM U897-Epidemiology-Biostatistics, Bordeaux, France; ‡The Donald K. Johnson Eye Center, The University Health Network, Toronto; The University of Toronto, Toronto, Canada; §University Eye Hospital Hannover, Hannover, Germany; ¶Montreal Retina Institute, Montreal, Canada; **Musgrove Park Hospital, Taunton, United Kingdom; ††Eye Clinic, Medical University, Göttingen, Germany; ‡‡Department of Medical and Biological Sciences, Ophthalmology, University of Udine, IEMO-Istituto Europeo di Microchirurgia Oculare, Udine, Italy; §§Department of Ophthalmology, City Hospital Triemli, Zurich; University of Zurich, Zurich, Switzerland; ¶¶Centre for Vision Research, Westmead Millennium Institute, University of Sydney, New South Wales, Australia; ***Macula and Retina Institute, Hospital Quiron Teknon, Barcelona; Barcelona Macula Foundation: Research for Vision, Barcelona, Spain; †††Retina Service and Mid Atlantic Retina, Wills Eye Hospital, Philadelphia, Pennsylvania; ‡‡‡Department of Ophthalmology, Hôpital Lariboisière, AP-HP, Université Paris 7 Sorbonne Paris Cité, Paris, France; §§§Newcastle Upon Tyne Hospitals NHS Trust, Newcastle Upon Tyne, United Kingdom; and ¶¶¶Department of Ophthalmology, Inselspital, University Hospital, University of Bern, Bern, Switzerland. · ·Retina · Pubmed #26076215.

ABSTRACT: PURPOSE: A review of treat-and-extend regimens (TERs) with intravitreal anti-vascular endothelial growth factor agents in retinal diseases. METHODS: There is a lack of consensus on the definition and optimal application of TER in clinical practice. This article describes the supporting evidence and subsequent development of a generic algorithm for TER dosing with anti-vascular endothelial growth factor agents, considering factors such as criteria for extension. RESULTS: A TER algorithm was developed; TER is defined as an individualized proactive dosing regimen usually initiated by monthly injections until a maximal clinical response is observed (frequently determined by optical coherence tomography), followed by increasing intervals between injections (and evaluations) depending on disease activity. The TER regimen has emerged as an effective approach to tailoring the dosing regimen and for reducing treatment burden (visits and injections) compared with fixed monthly dosing or monthly visits with optical coherence tomography-guided regimens (as-needed or pro re nata). It is also considered a suitable approach in many retinal diseases managed with intravitreal anti-vascular endothelial growth factor therapy, given that all eyes differ in the need for repeat injections. CONCLUSION: It is hoped that this practical review and TER algorithm will be of benefit to health care professionals interested in the management of retinal diseases.

2 Guideline Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). 2014

Schmidt-Erfurth, Ursula / Chong, Victor / Loewenstein, Anat / Larsen, Michael / Souied, Eric / Schlingemann, Reinier / Eldem, Bora / Monés, Jordi / Richard, Gisbert / Bandello, Francesco / Anonymous2770789. ·Department of Ophthalmology, Medical University, Vienna, Austria. · Oxford Eye Hospital, Oxford University Hospitals, Oxford, UK. · Department of Ophthalmology, Tel Aviv Medical Center, Tel Aviv, Israel. · Department of Ophthalmology, Glostrup Hospital and University of Copenhagen, Copenhagen, Denmark. · Hôpital Intercommunal de Créteil, Paris, France. · Medical Retina Unit and Ocular Angiogenesis Group, Department Of Ophthalmology, Academic Medical Center, Amsterdam, The Netherlands. · Department of Ophthalmology, Hacettepe University, School of Medicine, Ankara, Turkey. · Centro Médico TEKNON, Director Institut de la Màcula i de la Retina, Barcelona, Spain. · Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. · Department of Ophthalmology, University Vita-Salute; Scientific Institute San Raffaele, Milano, Italy. · ·Br J Ophthalmol · Pubmed #25136079.

ABSTRACT: TRIAL REGISTRATION NUMBER: NCT01318941.

3 Guideline [Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists for intravitreal treatment of macular edema in uveitis: Date: 02/07/2014]. 2014

Heiligenhaus, A / Bertram, B / Heinz, C / Krause, L / Pleyer, U / Roider, J / Sauer, S / Thurau, S / Anonymous5390789 / Anonymous5400789 / Anonymous5410789. ·Augenabteilung, St. Franziskus-Hospital Münster, Hohenzollernring 74, 48145, Münster, Deutschland, arnd.heiligenhaus@uveitis-zentrum.de. · ·Ophthalmologe · Pubmed #25118844.

ABSTRACT: -- No abstract --

4 Guideline Management paradigms for diabetic macular edema. 2014

Mitchell, Paul / Wong, Tien Yin / Anonymous4340773. ·Centre for Vision Research, Westmead Millennium Institute, University of Sydney, Sydney, Australia. · Singapore Eye Research Institute, Singapore National Eye Centre, National University of Singapore, Singapore. Electronic address: ophwty@nus.edu.sg. · ·Am J Ophthalmol · Pubmed #24269850.

ABSTRACT: PURPOSE: To provide evidence-based recommendations for diabetic macular edema (DME) management based on updated information from publications on DME treatment modalities. DESIGN: Perspective. METHODS: A literature search for "diabetic macular edema" or "diabetic maculopathy" was performed using the PubMed, Cochrane Library, and ClinicalTrials.gov databases to identify studies from January 1, 1985 to July 31, 2013. Meta-analyses, systematic reviews, and randomized controlled trials with at least 1 year of follow-up published in the past 5 years were preferred sources. RESULTS: Although laser photocoagulation has been the standard treatment for DME for nearly 3 decades, there is increasing evidence that superior outcomes can be achieved with anti-vascular endothelial growth factor (anti-VEGF) therapy. Data providing the most robust evidence from large phase II and phase III clinical trials for ranibizumab demonstrated visual improvement and favorable safety profile for up to 3 years. Average best-corrected visual acuity change from baseline ranged from 6.1-10.6 Early Treatment Diabetic Retinopathy Study (ETDRS) letters for ranibizumab, compared to 1.4-5.9 ETDRS letters with laser. The proportion of patients gaining ≥ 10 or ≥ 15 letters with ranibizumab was at least 2 times higher than that of patients treated with laser. Patients were also more likely to experience visual loss with laser than with ranibizumab treatment. Ranibizumab was generally well tolerated in all studies. Studies for bevacizumab, aflibercept, and pegaptanib in DME were limited but also in favor of anti-VEGF therapy over laser. CONCLUSIONS: Anti-VEGF therapy is superior to laser photocoagulation for treatment of moderate to severe visual impairment caused by DME.

5 Guideline Contemporary management of diabetic retinopathy in Canada: from guidelines to algorithm guidance. 2014

Hooper, Philip / Boucher, Marie-Carole / Colleaux, Kevin / Cruess, Alan / Greve, Mark / Lam, Wai-Ching / Shortt, Stanley / Tourville, Eric. ·Western University, London, Ont., Canada. · ·Ophthalmologica · Pubmed #24246998.

ABSTRACT: Recent advances in the therapeutic options and approaches for diabetic retinopathy (DR) and diabetic macular edema (DME) have resulted in improved visual outcomes for many patients with diabetes. Yet, they have also created many clinical dilemmas for treating ophthalmologists and retina specialists, including treatment selection, initiation, frequency and duration. With this in mind, a panel of Canadian retina specialists met and discussed the current clinical evidence as well as specific situations and scenarios commonly encountered in daily practice. They also shared their experiences and therapeutic approaches. This document, containing a consensus on treatment algorithms for various clinical scenarios, is the result of their lengthy and in-depth discussions and considerations. The intent is to provide a step-by-step approach to the treatment of DR and DME. Although clinicians are encouraged to use and refer to these algorithms as a guide for various situations, they are not meant to be a replacement for sound clinical judgment.

6 Guideline The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary. 2013

Chakravarthy, U / Williams, M / Anonymous1680766. ·Department of Ophthalmology, Queen's University Belfast, Belfast, UK. · ·Eye (Lond) · Pubmed #24158023.

ABSTRACT: -- No abstract --

7 Guideline [Age-related macular degeneration]. 2013

Conselho Brasileiro de Oftalmologia, ?. ·Projeto Diretrizes da Associação Médica Brasileira, São Paulo, SP, Brasil. diretrizes@amb.org.br ·Rev Assoc Med Bras · Pubmed #23582550.

ABSTRACT: -- No abstract --

8 Guideline [Statement of the German Ophthalmology Society, the Retina Society and the Professional Association of German Ophthalmologists for the treatment of macular edema in retinal vein occlusion: therapeutic strategies]. 2012

Anonymous1730725 / Anonymous1740725 / Anonymous1750725. · ·Ophthalmologe · Pubmed #22911358.

ABSTRACT: -- No abstract --

9 Guideline [Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists for intravitreal treatment of macular edema in uveitis]. 2012

Anonymous1280709 / Anonymous1290709 / Anonymous1300709. · ·Ophthalmologe · Pubmed #22274298.

ABSTRACT: -- No abstract --

10 Guideline [Intravitreal injections: AFSSAPS guide to good practice]. 2012

Bodaghi, B / Korobelnik, J F / Cochereau, I / Hajjar, J / Goebel, F / Dumarcet, N / Anonymous590709. ·Service d'Ophtalmologie, Assistance-Publique Hôpitaux de Paris, CHU Pitié-Salpêtrière, Université Pierre et Marie Curie, 47-83 bd de l'Hôpital, 75013, Paris, France. bahram.bodaghi@psl.aphp.fr · ·J Fr Ophtalmol · Pubmed #22226388.

ABSTRACT: Intravitreal injections are very commonly performed in the daily practice of Ophthalmology and become a leading procedure in the management of age-related macular degeneration, diabetic retinopathy, infectious endophthalmitis or retinitis, uveitis and retinal vein occlusions. Based on the comments of a group of experts, including ophthalmologists, pharmacists and hygienists, the French Agency for the Safety of Health Products (AFSSAPS) edited a guide to good practice of intravitreal injections, revisiting those previously published in 2006. The overall experience accumulated during time is a valuable source of information to determine the most appropriate protocol. Therefore, the simplification of the procedure is reasonably proposed even though safety remains a major issue, in order to avoid complications, especially infections.

11 Guideline Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. 2011

Anonymous1950703 / Anonymous1960703 / Aiello, Lloyd Paul / Beck, Roy W / Bressler, Neil M / Browning, David J / Chalam, K V / Davis, Matthew / Ferris, Frederick L / Glassman, Adam R / Maturi, Raj K / Stockdale, Cynthia R / Topping, Trexler M. ·Department of Ophthalmology, Harvard Medical School, Joslin Diabetes Center, Boston, Massachusetts, USA. · ·Ophthalmology · Pubmed #22136692.

ABSTRACT: OBJECTIVE: To describe the underlying principles used to develop a web-based algorithm that incorporated intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema (DME) in a Diabetic Retinopathy Clinical Research Network (DRCR.net) randomized clinical trial. DESIGN: Discussion of treatment protocol for DME. PARTICIPANTS: Subjects with vision loss resulting from DME involving the center of the macula. METHODS: The DRCR.net created an algorithm incorporating anti-VEGF injections in a comparative effectiveness randomized clinical trial evaluating intravitreal ranibizumab with prompt or deferred (≥24 weeks) focal/grid laser treatment in eyes with vision loss resulting from center-involved DME. Results confirmed that intravitreal ranibizumab with prompt or deferred laser provides superior visual acuity outcomes compared with prompt laser alone through at least 2 years. Duplication of this algorithm may not be practical for clinical practice. To share their opinion on how ophthalmologists might emulate the study protocol, participating DRCR.net investigators developed guidelines based on the algorithm's underlying rationale. MAIN OUTCOME MEASURES: Clinical guidelines based on a DRCR.net protocol. RESULTS: The treatment protocol required real-time feedback from a web-based data entry system for intravitreal injections, focal/grid laser treatment, and follow-up intervals. Guidance from this system indicated whether treatment was required or given at investigator discretion and when follow-up should be scheduled. Clinical treatment guidelines, based on the underlying clinical rationale of the DRCR.net protocol, include repeating treatment monthly as long as there is improvement in edema compared with the previous month or until the retina is no longer thickened. If thickening recurs or worsens after discontinuing treatment, treatment is resumed. CONCLUSIONS: Duplication of the approach used in the DRCR.net randomized clinical trial to treat DME involving the center of the macula with intravitreal ranibizumab may not be practical in clinical practice, but likely can be emulated based on an understanding of the underlying rationale for the study protocol. Inherent differences between a web-based treatment algorithm and a clinical approach may lead to differences in outcomes that are impossible to predict. The closer the clinical approach is to the algorithm used in the study, the more likely the outcomes will be similar to those published. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

12 Guideline [SERV clinical practice guidelines: management of retinal vein occlusion. Sociedad Española de Retina y Vitreo]. 2010

Gómez-Ulla, F / Abraldes, M J / Basauri, E / Fernández, M / García-Layana, A / Gili, P / Montero, J / Nadal, J / Morales, V / Saravia, M / Cabrera, F / Cervera, E / Anonymous2800675. ·Complejo Hospitalario Universitario de Santiago de Compostela, Instituto Tecnológico de Oftalmología, Santiago de Compostela, España. · ·Arch Soc Esp Oftalmol · Pubmed #21167436.

ABSTRACT: PURPOSE: A guidelines for the management of retinal vein occlusion is presented. This is necessary because at this moment several therapeutic alternatives have been developed although their role is not yet sufficiently defined. METHODS: Review of the literature for evidence published up to date. Relevant literature was identified and the level of evidence graded. Evidence was then assessed for consistency, applicability and clinical impact. The information was contrasted with those guides published in other countries. RESULTS: Taking into account the different options of treatment that are currently used, several modes of action are suggested. The role of the various complementary examinations are discussed and it is recommended that criteria for the treatment are based on clinical, angiographic, and tomographic findings. CONCLUSIONS: Although there is no overall consensus, these guidelines promote a good standard of clinical practise and provide an update of the management of retinal vein occlusion.

13 Guideline [Statement of the German Ophthalmological Society, the Retinological Society and the Professional Association of German Ophthalmologists on Therapy for Macular Oedema in Cases of Retinal Vein Occlusion]. 2010

Anonymous60665 / Anonymous70665 / Anonymous80665. · ·Klin Monbl Augenheilkd · Pubmed #20645226.

ABSTRACT: -- No abstract --

14 Guideline [Guidelines of clinical practice of the SERV (Spanish Retina and Vitreous Society): management of ocular complications of diabetes. Diabetic retinopathy and macular oedema]. 2009

Pareja-Ríos, A / Serrano-García, M A / Marrero-Saavedra, M D / Abraldes-López, V M / Reyes-Rodríguez, M A / Cabrera-López, F / López-Gálvez, M / Cardona-Guerra, P / Abreu-Reyes, P / Quijada-Fumero, E / Coronado-Toural, A / Gutiérrez-Sánchez, E / Gil-Hernández, M A / Valls-Quintana, P / Marín-Olmos, F / Navarro-Alemany, R. ·Hospital Universitario de Canarias, La Laguna, Tenerife, España. aparejar@gmail.com · ·Arch Soc Esp Oftalmol · Pubmed #19809923.

ABSTRACT: OBJECTIVE: Diabetes mellitus is considered the most common cause of blindness in the working population of industrialized countries, with diabetic macular edema being the most common cause of decreased visual acuity and proliferative diabetic retinopathy (PDR) being responsible for the most severe visual deficits. We have therefore tried to establish a guide for clinical intervention whose purpose is to provide orientation on the treatment of diabetic retinopathy and its complications. This is necessary at a time when many treatment options have emerged whose role is not yet fully defined. METHOD: A group of expert retina specialists selected by the SERV (Vitreous-Retina Spanish Society) assessed the published results of different treatment options currently available, suggesting lines of action according to the degree of diabetic retinopathy present and the presence or absence of macular edema. RESULTS: PDR is primarily treated with pan-retinal photocoagulation. For clinically significant diabetic macular edema without signs of vitreomacular traction, the treatment of choice continues to be focal/grid photocoagulation. Similarly, retinovitreal surgery is indicated for both conditions. The use of antiangiogenic drugs was also analyzed but remains inconclusive. CONCLUSION: Laser therapy is effective in the management of diabetic retinopathy and diabetic macular edema. The role of antiangiogenics is not yet sufficiently defined.

15 Guideline [Guidelines of clinical practice of the SERV: treatment of exudative age-related macular degeneration (AMD)]. 2009

Ruiz-Moreno, J M / Arias-Barquet, L / Armadá-Maresca, F / Boixadera-Espax, A / García-Layana, A / Gómez-Ulla-de-Irazazábal, F / Monés-Carilla, J / Piñero-Bustamante, A / Suárez-de-Figueroa, M / Anonymous5150639. ·Catedrático de Oftalmología de la Universidad de Castilla - La Mancha, Instituto Oftalmológico Alicante (VISSUM), Red Temática de Investigación Cooperativa (RTICS) en Oftalmología, Albacete, España. JoseMaria.Ruiz@uclm.es · ·Arch Soc Esp Oftalmol · Pubmed #19658051.

ABSTRACT: OBJECTIVE: Age related macular degeneration (ARMD) in its neovascular form is a serious disease which produces legal blindness in many patients with poor prognosis if left untreated. We intend to establish a clinical guide with the different therapeutic options that exist nowadays, which may help the ophthalmologists in their clinical practice. METHODS: A group of medical retina experts selected by SERV have evaluated the results of different published studies with the drugs currently available, obtaining an evidence-based consensus. Some recommendations have been established for diagnosis, treatment and monitoring of patients with neovascular ARMD. RESULTS: The intravitreal injection of ranibizumab at a dosage of 0.5 mg produces significant improvement of visual acuity in subfoveal lesions, according to data obtained from studies with the highest level of evidence. It should be considered as a first choice drug. The use of bevacizumab, a drug with not approved indication for intraocular use, nor for the treatment of neovascular ARMD can reach a result which is closer to the ones obtained with ranibizumab than to those obtained with photodynamic therapy (PDT) and pegaptanib. The use of intravitreal pegaptanib sodium in intravitreal injection at a dosage of 0.3 mg as a treatment for subfoveal lesions can obtain similar results to the TFD, but with a wider range of injuries. CONCLUSION: The results of the evidence-based studies are a good guide for the treatment of this disease.

16 Guideline Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment. 2009

Amoaku, W / Anonymous710646 / Anonymous720646 / Anonymous730646. ·Scientific Department, The Royal College of Ophthalmologists, Regent's Park, UK. Wma@nottingham.ac.uk · ·Eye (Lond) · Pubmed #18670458.

ABSTRACT: -- No abstract --

17 Guideline [Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration]. 2007

Anonymous2770589. · ·Klin Monbl Augenheilkd · Pubmed #17657689.

ABSTRACT: The basic conditions in the management of exudative age-related macular degeneration have changed considerably since the last statement of the German professional associations in 2006. While Pegaptanib was approved in Germany already in 2006 Ranibizumab was approved for the treatment of exudative macular degeneration in Germany in February 2007. More over the quality assurance regulations for the photodynamic treatment of choroidal neovascularizations with Verteporfin were modified including the treatment of occult lesions and implementing a simplified classification of extra- and subfoveal lesions. Consequently modification of the recommendations for the non-surgical treatment of exudative age-related macular degeneration appeared inevitable.

18 Editorial Ophthalmic Technology Assessments. 2015

Jampel, Henry D. ·Baltimore, Maryland. Electronic address: hjampel@jhmi.edu. ·Ophthalmology · Pubmed #26498079.

ABSTRACT: -- No abstract --

19 Editorial Should We Add Screening of Age-Related Macular Degeneration to Current Screening Programs for Diabetic Retinopathy? 2015

Chew, Emily Y / Schachat, Andrew P. ·Bethesda, Maryland. Electronic address: echew@nei.nih.gov. · Cleveland, Ohio. ·Ophthalmology · Pubmed #26498078.

ABSTRACT: -- No abstract --

20 Editorial Ranibizumab: reject such high (exorbitant) prices. 2015

Anonymous3740812. · ·Prescrire Int · Pubmed #26417626.

ABSTRACT: -- No abstract --

21 Editorial Lifestyles and Cognitive Health: What Older Individuals Can Do to Optimize Cognitive Outcomes. 2015

Gill, Sudeep S / Seitz, Dallas P. ·Department of Medicine, Queen's University, Kingston, Ontario, Canada. · Department of Psychiatry, Queen's University, Kingston, Ontario, Canada. ·JAMA · Pubmed #26305645.

ABSTRACT: -- No abstract --

22 Editorial Anti-Vascular Endothelial Growth Factor Injections and Intraocular Pressure Measurement: Should We Throw the Baby out with the Bath Water? 2015

Jampel, Henry / Kalenak, Jeffrey. ·Baltimore, Maryland. · Milwaukee, Wisconsin. ·Ophthalmology · Pubmed #26299718.

ABSTRACT: -- No abstract --

23 Editorial Preface. 15th European Meeting on Complement in Human Disease 2015, Uppsala, Sweden. 2015

Nilsson, Bo / Ekdahl, Kristina Nilsson / Kemper, Claudia / Mollnes, Tom Eirik. ·University of Uppsala, Sweden. Electronic address: bo.nilsson@igp.uu.se. · University of Uppsala, Sweden. Electronic address: Kristina.Nilsson_Ekdahl@igp.uu.se. · King's College London, UK. Electronic address: Claudia.kemper@kcl.ac.uk. · Nordland Hospital, Bodø, Norway; University of Tromsø, Norway. Electronic address: t.e.mollnes@medisin.uio.no. ·Mol Immunol · Pubmed #25934434.

ABSTRACT: -- No abstract --

24 Editorial A licence to cure. 2015

Aronson, Jeffrey K / Ferner, Robin E. ·Nuffield Department of Primary Care Health Sciences, Oxford OX2 6GG, UK jeffrey.aronson@phc.ox.ac.uk. · West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, UK. ·BMJ · Pubmed #25834026.

ABSTRACT: -- No abstract --

25 Editorial Clinical trials: a need to better define the control group as current standard of care. 2015

Bakri, Sophie J. ·Rochester, Minnesota. ·Ophthalmology · Pubmed #25703467.

ABSTRACT: -- No abstract --

Next